Ruboxistaurin HCl

• CAT Number: I009230
• CAS Number: 169939-93-9 (HCl)
• Molecular Formula: C28H29ClN4O3
• Molecular Weight: 505.02
• Purity: ≥95%
• Synonyms: Ruboxistaurin; Ruboxistaurin hydrochloride, LY-333531; LY333531; LY 333531.;(12E,32E,7S)-7-((dimethylamino)methyl)-22,25-dihydro-11H,21H,31H-6-oxa-1,3(3,1)-diindola-2(3,4)-pyrrolacyclononaphane-22,25-dione hydrochloride
• Target: PKCbeta inhibitor
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: 18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione;hydrochloride
• InChI: InChI=1S/C28H28N4O3.ClH/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24;/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34);1H/t18-;/m0./s1
• InChIKey: NYQIEYDJYFVLPO-FERBBOLQSA-N
• SMILES: CN(C)CC1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O.Cl

Ruboxistaurin HCl(CAT: I009230) is a selective inhibitor of protein kinase C beta (PKCβ), an enzyme implicated in the pathophysiology of diabetic complications. By inhibiting PKCβ activity, Ruboxistaurin HCl reduces abnormal signaling pathways associated with hyperglycemia, such as vascular dysfunction and inflammation. This compound has been investigated primarily for its therapeutic potential in diabetic retinopathy and other microvascular complications of diabetes. Its targeted mechanism of action makes it a valuable tool in metabolic and vascular research, providing insights into PKCβ-mediated processes and aiding in the development of treatments for diabetes-related vascular disorders.